|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:ageRange
|
18 Years and older
|
|
gptkbp:allocates
|
Randomized
|
|
gptkbp:clinicalTrialPhase
|
Phase 3
|
|
gptkbp:clinicalTrialsGovIdentifier
|
gptkb:NCT03775200
|
|
gptkbp:completedIn
|
June 2021
|
|
gptkbp:conditionStudied
|
Generalized Myasthenia Gravis
|
|
gptkbp:enrollment
|
110
|
|
gptkbp:gender
|
All
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
NCT03775200
|
|
gptkbp:intervention
|
gptkb:Placebo
Efgartigimod PH20 SC
|
|
gptkbp:location
|
gptkb:Europe
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mask
|
Double (Participant, Investigator)
|
|
gptkbp:officialName
|
A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Generalized Myasthenia Gravis (ADAPT-SC)
|
|
gptkbp:primaryCompletionDate
|
April 2021
|
|
gptkbp:primaryOutcomeMeasure
|
Percentage of participants with at least a 2-point improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) score
|
|
gptkbp:sponsor
|
argenx BVBA
|
|
gptkbp:startDate
|
December 18, 2018
|
|
gptkbp:studyType
|
Interventional
|
|
gptkbp:bfsParent
|
gptkb:COMP360_(psilocybin_therapy)
|
|
gptkbp:bfsLayer
|
8
|